Plain-English translation of NCT07182279 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a treatment approach for men with aggressive prostate cancer that hasn't spread beyond the prostate. Participants will receive a single dose of high-dose-rate (internal radiation) 4 to 8 weeks before having their prostate surgically removed. Some participants may also receive hormone-blocking medication afterward, depending on how aggressive their cancer appears under genetic testing.
For men with aggressive prostate cancer, doctors want to know if giving radiation before surgery can improve outcomes and prevent the cancer from coming back. This trial will help determine if this combination approach is safe and effective.
You likely qualify if…
You likely don't qualify if…
You will receive a single treatment of internal radiation () to your prostate. Then, 4 to 8 weeks later, you will have surgery to remove your prostate using minimally invasive robotic techniques. Depending on your cancer's genetic profile and what doctors find during surgery, you may receive 3 months of hormone-blocking medication afterward. You'll be in the study for up to 27 months total, with follow-up visits for 2 years after surgery to monitor your recovery and cancer status.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States